How do you think the new GigE standards will influence the machine vision industry?
Respond or ask your question now!
TORONTO, ONTARIO--(CCNMatthews - Jan. 19, 2006) -
Attention: Business/Financial Editors:
The Medipattern Corporation (TSX VENTURE:MKI), a leading developer of computer-aided detection (CAD) software applications for medical imaging, is pleased to announce that its CAD for MRI (B-CAD MRI(TM)) has won the 2006 Medical Imaging Technology Innovation of the Year Award, presented by the analyst team of Frost & Sullivan, a leading global provider of industry analysis and research. The Award is presented to the company that has demonstrated technological superiority within its industry, and recognizes the ability of the company to successfully develop and introduce new technology, formulate a well-designed product family, and make significant product performance contributions to the industry.
Frost & Sullivan made the award on the basis of the technology innovation of Medipattern's B-CAD MRI in contrast to competitors, its ability to compare features in both MRI and ultrasound, and particularly noted both Medipattern's crossing of the modality barrier from ultrasound to MRI, and its focus on identification and analysis of morphological features of lesions in breast images. On the basis of its research, Frost & Sullivan expects the unique technology to be quickly and widely adopted by a wide range of end-users, from hospitals to diagnostic imaging centres.
Frost & Sullivan also noted that Medipattern's B-CAD MRI complies with American College of Radiology (ACR) BI-RADS(R) guidelines for ultrasound and MRI procedures in breast imaging. The research team at Frost & Sullivan indicated that Medipattern's B-CAD MRI is, to date, the only CAD for MRI to use both kinetics -- where the wash-in, wash-out time of contrast agent is used to predict whether tissue is cancerous -- and morphology -- where gross and acute analysis of physical characteristics has high positive and negative predictive value. According to Frost & Sullivan, radiologists suggest that MRI CAD software that can combine both kinetic and morphological analysis holds the potential to significantly reduce or avoid the need for biopsy, while detecting subtle tissue changes that occur pre-metastasis.
Non-invasive, Medipattern's technology also has the potential to markedly improve patient experience. The Company will seek FDA approval for the software, with general market availability expected in the Fall of 2006.
"This broadly recognized award gives Medipattern powerful industry validation of the approach we have been taking with our CAD platform, Cadenza(TM)," said Jeff Collins, President and CEO of Medipattern. "Frost & Sullivan recognized not only Medipattern's B-CAD MRI, but the strength and flexibility of our overall platform, and the ability to navigate between both ultrasound and MRI data within the same software application. Frost & Sullivan's Innovation Award is its highest honor and highlights the industry's belief in the strategic direction Medipattern has chosen."